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S U M M A R Y
Background: Current guidelines for treating community-acquired pneumonia recommend the use of
ﬂuoroquinolones for high-risk patients. Previous studies have reported controversial results as to
whether ﬂuoroquinolones are associated with delayed diagnosis and treatment of pulmonary
tuberculosis (TB) and the development of ﬂuoroquinolone-resistant Mycobacterium tuberculosis. We
performed a systematic review and meta-analysis to clarify these issues.
Methods: The following databases were searched through September 30, 2010: PubMed, EMBASE,
CINAHL, Cochrane Library, Web of Science, BIOSIS Previews, and the ACP Journal Club. We considered
studies that addressed the issues of delay in diagnosis and treatment of TB and the development of
resistance.
Results: Nine eligible studies (four for delays and ﬁve for resistance issues) were included in the meta-
analysis from the 770 articles originally identiﬁed in the database search. The mean duration of delayed
diagnosis and treatment of pulmonary TB in the ﬂuoroquinolone prescription group was 19.03 days,
signiﬁcantly longer than that in the non-ﬂuoroquinolone group (95% conﬁdence interval (CI) 10.87 to
27.18, p < 0.001). The pooled odds ratio of developing a ﬂuoroquinolone-resistantM. tuberculosis strain
was 2.70 (95% CI 1.30 to 5.60, p = 0.008). No signiﬁcant heterogeneity was found among studies in the
meta-analysis.
Conclusions: Empirical ﬂuoroquinolone prescriptions for pneumonia are associatedwith longer delays in
diagnosis and treatment of pulmonary TB and a higher risk of developing ﬂuoroquinolone-resistant M.
tuberculosis.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The Infectious Diseases Society of America and the American
ThoracicSociety (IDSA/ATS)haverecommendedtheuseof respiratory
ﬂuoroquinolones for the treatment of adult community-acquired
pneumonia in the presence of co-morbidities or risk factors for drug-
resistant Streptococcus pneumoniae.1 Empirical treatment of commu-
nity-acquired pneumonia with ﬂuoroquinolones raises great con-
cerns about delayed diagnosis and treatment of pulmonary
tuberculosis (TB) and the development of ﬂuoroquinolone-resistant
Mycobacterium tuberculosis.2 Several case reports have demonstrated
that the administration of ﬂuoroquinolones may delay the diagnosis
of pulmonary TB and lead to the emergence of ﬂuoroquinolone-
resistantM. tuberculosis;3–8 in particular, Singh indicated that the use
of ﬂuoroquinolones in endemic areaswould increase the potential for* Corresponding author. Tel.: +886 7 312 1101x5677; fax: +886 7 322 8547.
E-mail address: d810070@cc.kmu.edu.tw (Y.-H. Chen).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.11.008masking active TB and the emergence of an epidemic of widespread
drug-resistant M. tuberculosis.9 To determine whether ﬂuoroquino-
lone prescriptions are associated with delayed diagnosis and
treatment of pulmonary TB and the development of ﬂuoroquino-
lone-resistantM. tuberculosis, we performed a systematic review and
meta-analysis for these two issues.
2. Materials and methods
2.1. Search strategy and study selection
We followed the recommendations of the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement to conduct this systematic review.10Weused theMedical
Subject Heading (MeSH) terms of ‘ﬂuoroquinolones/quinolones’
(also including all ﬂuoroquinolones approved by the US Food and
Drug Administration, such as ciproﬂoxacin, oﬂoxacin, norﬂoxacin,
levoﬂoxacin, moxiﬂoxacin, and gemiﬂoxacin) and ‘tuberculosis’,
combined with ‘delay’ or ‘resistant/ce’, to search the databases ofses. Published by Elsevier Ltd. All rights reserved.
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Previews, and ACP Journal Club through September 30, 2010. The
articles were selected with no language restriction. We included
prospective and retrospective cohort studies, case–control studies,
and randomized control trials that addressed the two issues: (1)
Whether ﬂuoroquinolone prescriptions are associatedwith delayed
diagnosis and treatment of pulmonary TB or (2) whether
ﬂuoroquinolone prescriptions are associated with the development
of ﬂuoroquinolone-resistant M. tuberculosis. The duration of delays
and resistance rates for ﬂuoroquinolones after the use of ﬂuor-
oquinolones before the diagnosis of TBwere criteria for inclusion in
the meta-analysis. Case reports were excluded.
2.2. Data extraction
The data were abstracted by two independent reviewers (T.-C.
Chen and C.-Y. Lin) using a standardized protocol and deﬁnitions.
Disagreement on speciﬁc studies between the two reviewers was
resolved through discussion. The reviewers abstracted the dura-
tion of delays and resistance rates for ﬂuoroquinolones after using
ﬂuoroquinolones before a diagnosis of TB was made. The duration
of delayed diagnosis and treatment for pulmonary TB was deﬁned
as the time interval from presenting to the hospital system (health
care delays) or the initiation of antibiotics (antibiotic delays) to the
initiation of anti-TB medications. Because the presentations of
delays are different, one study used mean and standard deviations
(SDs) and the others used median and range or interquartile range
(IQR). In our analysis, we assumed the median to be equal to the
mean, the IQR to be 1.35  SD, and the range to be 4  SD,[(Figure_1)TD$FIG]Records identified for TB delayed 
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Figure 1. Selection of the studies iaccording to the instructions in the statistical software used. A
ﬂuoroquinolone prescription-associated ﬂuoroquinolone-resis-
tant TB included any isolate from a patient who had any kind of
ﬂuoroquinolone prescribed within 12 months before the ﬂuoro-
quinolone-resistant TB culture was obtained.
2.3. Statistical analysis
Data were combined using a random-effects model, which
assumes that individual studies are estimating different treatment
effects, rather than the ﬁxed-effects model, which is based on the
mathematical assumption that a single common effect underlies
every study in the meta-analysis. Statistical heterogeneity was
evaluated using the Cochran Q test (a Chi-square test for
heterogeneity) and the I2 statistic. ‘I2’ denotes the percentage of
total variation across the studies that is the result of heterogeneity
rather than chance. We assessed for the presence of publication
bias using a funnel plot. The meta-analysis was performed using
Review Manager Version 5.0.24 (Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2008). A p-value
of <0.05 was considered statistically signiﬁcant.
3. Results
Initially, 770 abstracts were identiﬁed from the database search
and then 33 relevant articles were selected for critical evaluation.
Nine eligible studies (four for delays and ﬁve for resistance
issues)11–19 were included in the ﬁnal meta-analysis (Figure 1 and
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Table 1
Summary of the nine studies eligible for the meta-analysis
Author, publication year [Ref.] Country Years Study design and population characteristics Sample size Median or mean FQ exposure/FQ
prescriptions (No.)
Effects
Whether ﬂuoroquinolone prescriptions are associated with delayed diagnosis and treatment of pulmonary TB
Dooley, 2002 [11] USA 1998– 2001 Retrospective, all newly diagnosed, culture-positive,
age 18 years, pulmonary TB cases
Excluded: no respiratory symptoms and no use of
antibiotics
FQ: 16
Non-FQ: 17
NA/Levo (11), Gati (1), Trova (2),
Cipro (1), Cipro!Trova (1)
Health care delays:
FQ: 21 days (IQR 5–32)
Non-FQ: 5 days (IQR 1–16)
Yoon, 2005 [14] Korea 2000– 2004 Retrospective, all newly diagnosed, culture-positive,
FQ or other antibiotic treatment >5 days, pulmonary
TB cases
Excluded: coexisting bacterial infection
FQ: 9
Non-FQ: 19
14.28.3 days/Levo (7), Cipro (2) Antibiotic delays:
FQ: 43.140.0 days
Non-FQ: 18.716.9 days
Golub, 2005 [13] USA 2000– 2001 Prospective, all newly diagnosed, culture-positive,
pulmonary TB cases
FQ: 45
Non-FQ: 40
NA/NA Antibiotic delays:
FQ: 29 days
Non-FQ: 31 days
Wang, 2006 [15] Taiwan 2002– 2003 Retrospective, all newly diagnosed, culture-positive,
age 14 years, pulmonary and extrapulmonary
TB cases
FQ: 79
Non-FQ: 218
9.56.0 days/Cipro (42), Levo (21),
Moxi (16)
Health care delays:
FQ: 41 days (range 6–233 days)
Non-FQ: 16 days (range 0–198
days)
Whether ﬂuoroquinolone prescriptions are associated with development of ﬂuoroquinolone-resistant
Mycobacterium tuberculosis
Ginsberg, 2003 [12] USA 1998– 2002 Retrospective, all newly diagnosed, culture-positive,
age 18 y, pulmonary TB (29), extrapulmonary TB
(19), and both (7)
FQ: 19
Non-FQ: 36
4 days/NA FQ: 1.5% FQ resistance
Non-FQ: 0% FQ resistance
Wang, 2007 [16] Taiwan 2004– 2005 Retrospective, pulmonary TB (380), extrapulmonary
TB (23), and both (17)
FQ: 108
Non-FQ: 312
7 days/NA FQ: 4.6% FQ resistance
Non-FQ: 2.9% FQ resistance
Park, 2007 [17] Korea 1997– 2005 Retrospective, culture-positive, pulmonary and
extrapulmonary TB
FQ: 39
Non-FQ: 2749
7 days/Cipro (23), Levo (11), Moxi (3),
Tosu (2)
FQ: 2.6% FQ resistance
Non-FQ: 3.4% resistance
Devasia, 2009 [18] USA 2002– 2006 Retrospective, all newly diagnosed, culture-positive,
pulmonary
TB (500), extrapulmonary TB (77), and both (63)
FQ: 116
(264 courses)
Non-FQ: 524
FQ-resistant 30.5 days; FQ-susceptible
10 days/Levo (147), Cipro (78),
Moxi (20)
FQ: 6.9% FQ resistance
Non-FQ: 1.7% FQ resistance
Long, 2009 [19] Canada 1996– 2003 Retrospective, all newly diagnosed, culture-positive,
age 14 y, pulmonary TB cases
FQ: 74
Non-FQ: 74
Multiple FQ prescription: 16 days;
single FQ prescription: 7 days/NA
FQ: 4.1% FQ resistance
Non-FQ: 0% FQ resistance
TB, tuberculosis; FQ, ﬂuoroquinolone; NA, data not available; IQR, interquartile range; Levo, levoﬂoxacin; Cipro, ciproﬂoxacin; Moxi, moxiﬂoxacin; Gati, gatiﬂoxacin; Trova, trovaﬂoxacin; Tosu, tosuﬂoxacin; NA, data not available.
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Figure 2. Forest plots of the studies showing the association between ﬂuoroquinolone prescription and the duration of delayed diagnosis and treatment of pulmonary TB (A),
and health care delays (B) and antibiotic delays (C) in the management of pulmonary TB.
T.-C. Chen et al. / International Journal of Infectious Diseases 15 (2011) e211–e216214Funnel plot analysis did not suggest signiﬁcant publication bias
for these meta-analyses. The mean duration of delayed diagnosis
and treatment of pulmonary TB (pooled health care and antibiotic
delays) in the ﬂuoroquinolone prescription group was 19.03 days,
signiﬁcantly longer than in the non-ﬂuoroquinolone group (95%
conﬁdence interval (CI) 10.87 to 27.18, p < 0.001). No statistically
signiﬁcant heterogeneity was found among the studies (I2 = 0%,
p = 0.54; Figure 2A). The mean duration of health care delay in the[(Figure_3)TD$FIG]
Figure 3. Forest plot of the ﬁve studies showing the association between ﬂuoroquinolon
tuberculosis.ﬂuoroquinolone group was 19.44 days, signiﬁcantly longer than in
the non-ﬂuoroquinolone group (95% CI 10.70 to 28.19, p < 0.001;
Figure 2B), but the mean difference of antibiotic delay was not
signiﬁcant (15.69 days, 95% CI 8.65 to 40.02, p = 0.29; Figure 2C).
The pooled odds ratio of developing a ﬂuoroquinolone-resistant TB
strain was 2.70 (95% CI 1.30 to 5.60, p = 0.008). No statistically
signiﬁcant heterogeneity was found among these studies (I2 = 10%,
p = 0.35; Figure 3).e prescription and the risk of developing ﬂuoroquinolone-resistant Mycobacterium
T.-C. Chen et al. / International Journal of Infectious Diseases 15 (2011) e211–e216 e2154. Discussion
Both the IDSA/ATS and the European guidelines20 for the
management of community-acquired pneumonia recommend
respiratory ﬂuoroquinolones as the drugs of choice or alternative
choices for treating community-acquired pneumonia. However,
the British21 and Australian guidelines22 for managing communi-
ty-acquired pneumonia do not include the ﬂuoroquinolones as
ﬁrst-line agents for treatment. The reasons for the differences in
these guidelines are based on the rates of penicillin-resistant
pneumococci, which are lower in Australia and the UK than in the
USA, and concerns regarding ﬂuoroquinolone resistance.21,22
Our meta-analysis showed a 19-day delay in the diagnosis and
treatment of pulmonary TB with the prescription of ﬂuoroquino-
lones, longer than that with the prescription of non-ﬂuoroquino-
lone antibiotics, and a 2.7-fold higher risk of developing
ﬂuoroquinolone-resistant TB strains. Fluoroquinoloneswere found
to be effective for M. tuberculosis, and respiratory symptoms and
results seen on chest radiography usually improved under
ﬂuoroquinolone monotherapy.11,13–15 However, such therapy will
mask and delay the diagnosis of TB. Two studies also showed that
inappropriate prescribing patterns for antibiotics in treating
respiratory tract infections can delay the diagnosis of pulmonary
TB and play a role in the development of drug-resistant M.
tuberculosis.23,24 Two animal studies demonstrated that ﬂuoro-
quinolone monotherapy will cause the emergence of ﬂuoroquino-
lone-resistant M. tuberculosis, which is not due to poor microbial
kill but to rapid emergence of resistance.25,26 Another interesting
question is the relationship between the duration of ﬂuoroquino-
lone use and the development of resistance to the ﬂuoroquinolone.
Previous reports showed short-term exposure to ﬂuoroquinolones
not to be associated with the development of ﬂuoroquinolone
resistance. In recent studies, however, multiple ﬂuoroquinolone
prescriptions19 and the use of a ﬂuoroquinolone for >10 days18
have been linked to ﬂuoroquinolone-resistant tuberculosis. In
addition, Chang et al.27 also indicated that the duration of exposure
tomoxiﬂoxacin had a dose–response relationship tomasking TB in
a TB endemic area. Levoﬂoxacin and ciproﬂoxacin were the most
prescribed ﬂuoroquinolones, but this meta-analysis could not
address the effects of the different ﬂuoroquinolones on delays or
resistance. Older ﬂuoroquinolones, such as ciproﬂoxacin, had
higher minimal inhibitory concentrations against M. tuberculosis
and were ineffective in treating TB, with higher failure rates
clinically.28 Ciproﬂoxacin was not recommended for treating TB
and may create a higher risk of developing resistance.
Factors associated with TB diagnostic delays included infection
with HIV, coexistence of chronic cough or other lung diseases,
negative sputum smear, extrapulmonary TB, rural residence, low
access to health care/facilities, older age, female sex, alcoholism or
substance abuse, stigma of being a person with TB infection, and
low psychosocial status.29 In this meta-analysis, being elderly,15,19
having extrapulmonary TB,12,18 and carrying an HIV infection11
were associated with delayed diagnosis or ﬂuoroquinolone
resistance. Another report from our hospital also showed exposure
to ﬂuoroquinolones in addition to negative sputum smear, non-
cavitary lung lesions, admission to non-chest medicine/infectious
diseases wards, and age >65 years as independent risk factors for
in-hospital delay of diagnosis of pulmonary TB.30
However, this analysis has some limitations. First, the issue of
most concern was the use of ﬂuoroquinolones in patients with
community-acquired pneumonia. However, the enrolled popula-
tions in the meta-analysis varied. Four studies included patients
with extrapulmonary TB in addition to pulmonary TB15–17 and only
one studywas prospective.13 The prescriptions of ﬂuoroquinolones
were not only for respiratory tract infections, but also for urinary
tract infections, wound infections, etc. A recent retrospective studyof extrapulmonary TB demonstrated that ﬂuoroquinolone mono-
therapy of unsuspected renal TB may delay diagnosis and lead to
ﬂuoroquinolone resistance.31 Therefore, delayed diagnosis and
ﬂuoroquinolone resistance should also be considered and lead to
caution in the use of ﬂuoroquinolone treatment for urinary tract
infections. Second, the deﬁnitions of delay differed. Two studies
assessed health care delays11,15 rather than antibiotic delays. In our
study, the pooled health care and antibiotic delay and health care
delay only were of longer duration in the ﬂuoroquinolone
prescription group than in the non-ﬂuoroquinolone prescription
group, but not for antibiotic delay only. Thus, further prospective
studies with larger populations are necessary to validate the
results.
In conclusion, this meta-analysis suggests that empirical
prescriptions of ﬂuoroquinolones for pneumonia are associated
with longer delays in the diagnosis and treatment of pulmonary TB
and a higher risk of developing ﬂuoroquinolone-resistant TB. In
patients with pneumonia, the possibility of pulmonary TB should
be considered before a ﬂuoroquinolone is prescribed to avoid the
consequences of delayed management of TB and the development
of ﬂuoroquinolone-resistant TB.
Conﬂict of interest: No conﬂict of interest to declare.
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